SCHEMBL1067741

SCHEMBL1067741

CCOC(=O)C(CC(C)CC)N=C(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
AAK1 Q2M2I8 1/20 0.45
PIN1 Q13526 1/20 0.40
MAPT P10636 3/20 0.39
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 1/20 0.38
PGR P06401 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
HTR2A P28223 1/20 0.38
HRH1 P35367 1/20 0.38
KCNH2 Q12809 1/20 0.38
MMP8 P22894 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TBXAS1 P24557 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1067740 1.00 MEN1 (0.46) MEN1KMT2ANPC1AAK1PIN1
SCHEMBL5928301 0.87 MEN1 (0.51) MEN1KMT2ANPC1AAK1PIN1
SCHEMBL1068927 0.85 AAK1 (0.43) MEN1KMT2AAAK1MAPTALDH1A1
SCHEMBL1068928 0.85 AAK1 (0.43) MEN1KMT2AAAK1MAPTALDH1A1
SCHEMBL17005451 0.84 AAK1 (0.49) MEN1KMT2ANPC1AAK1PIN1
SCHEMBL14493754 0.81 AAK1 (0.54) MEN1KMT2ANPC1AAK1PIN1
SCHEMBL1068082 0.80 AAK1 (0.56) MEN1KMT2ANPC1AAK1PIN1
SCHEMBL1661845 0.79 MEN1 (0.53) MEN1KMT2ANPC1AAK1PIN1
SCHEMBL9847924 0.79 MEN1 (0.53) MEN1KMT2ANPC1AAK1PIN1
SCHEMBL30762080 0.79 MEN1 (0.53) MEN1KMT2ANPC1AAK1PIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102007118-B Pyrrolidinone glucokinase activators HOFFMANN LA ROCHE 2014-12-31 CN disclosed
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 MEN1 2997/4885KMT2A 2072/4885NPC1 3656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.